Biogen's (NASDAQ: BIIB ) Tecfidera launched a year ago, and it has already become a blockbuster likely to notch more than $2 billion in sales this year. Much of Tecfidera's success is coming at the expense of recently launched oral multiple sclerosis drugs from Novartis (NYSE: NVS ) and Sanofi (NYSE: SNY ) , which market Gilenya and Aubagio, respectively.
As Tecfidera rolls out globally, Novartis and Sanofi are likely to lose additional market share over the coming year, but neither company is sitting still. Both are among a slate of generic drug makers that have filed opposition to a key EU patent on Tecfidera that gives Tecfidera exclusivity until 2028.
In the following slideshow, you'll learn more about the patent threat to Biogen's fast growing drug and what the impact on Biogen may be if the EU's patent office sides with Novartis and Sanofi.
Leaked: This coming blockbuster will make Biogen jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns, you will need The Motley Fool's new free report on the dream team responsible for this game-changing blockbuster. CLICK HERE NOW.